Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen
| Autor: | Farshad Guirakhoo, Thomas P. Monath, Sutee Yoksan, Robert Schrader, Philip Bedford, Danell Mathis, Christopher J. Murphy, Karen McCarthy, Casey Johnson, Richard A. Nichols, Paul S. Blum, Stephen Woodward |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Genetic Vectors
Antibodies Viral Vaccines Attenuated Mice Double-Blind Method Neutralization Tests medicine Immunology and Allergy Animals Humans West Nile Virus Vaccines Japanese encephalitis vaccine Neutralizing antibody Adverse effect Encephalitis Japanese Antigens Viral Immunization Schedule Encephalitis Virus Japanese Attenuated vaccine biology Dose-Response Relationship Drug business.industry Japanese Encephalitis Vaccines Immunogenicity Vaccination Yellow Fever Vaccine Viral Vaccines Japanese encephalitis medicine.disease Virology Infectious Diseases Treatment Outcome Vaccines Inactivated Immunology biology.protein Yellow fever virus business Immunologic Memory Encephalitis medicine.drug |
| Zdroj: | The Journal of infectious diseases. 188(8) |
| ISSN: | 0022-1899 |
| Popis: | ChimeriVax-JE is a live, attenuated vaccine against Japanese encephalitis, using yellow fever (YF) 17D vaccine as a vector. In a double-blind phase 2 trial, 99 adults received vaccine, placebo, or YF 17D vaccine (YF-VAX). ChimeriVax-JE was well tolerated, with no differences in adverse events between treatment groups. Viremias resulting from administration of ChimeriVax-JE and YF-VAX were of short duration and low titer; 82 (94%) of 87 subjects administered graded doses (1.8-5.8 log(10)) of ChimeriVax-JE developed neutralizing antibodies. A second dose, administered 30 days later, had no booster effect. Previous inoculation with YF did not interfere with ChimeriVax-JE, but there was a suggestion (not statistically significant) that ChimeriVax-JE interfered with YF-VAX administered 30 days later. A separate study explored immunological memory both in subjects who had received ChimeriVax-JE 9 months before and in ChimeriVax-JE-naive subjects challenged with inactivated mouse-brain vaccine (JE-VAX). Anamnestic responses were observed in preimmune individuals. ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|